UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Date of Report: April 14, 2015
Commission File Number: 001-36891
Cellectis S.A.
(Exact Name of registrant as specified in its charter)
8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXHIBIT INDEX
| Exhibit |
Title | |
| 99.1 | Press release, dated April 14, 2015. | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CELLECTIS S.A. | ||||||
| (Registrant) | ||||||
| April 14, 2015 | By: | /s/ André Choulika | ||||
| André Choulika | ||||||
| Chief Executive Officer | ||||||
3
PRESS RELEASE
Cellectis Plant Sciences, Inc. Publishes a Study Demonstrating
Reduced Acrylamide in Fried Potatoes
April 14, 2015 — New Brighton (Minnesota, USA) — Cellectis Plant Sciences, Inc. a Minnesota-based company focusing on developing healthier food products, has announced today that the Plant Biotechnology Journal has accepted the publication of its peer-reviewed manuscript demonstrating the phenotypic validation of potato lines developed by inactivating a single endogenous gene responsible for sugar accumulation when stored at cold temperatures.
The non-transgenic product has already received an approval from the USDA to be grown in fields. The field trial will start this spring to obtain commercial proof of concept of large-scale cold storability and reduced acrylamide content for French fries, potato chips and fresh-cut applications.
“We firmly believe that the new product developed by our team opens the path to the future of food products,” commented Luc Mathis, Chief Executive Officer of Cellectis Plant Sciences. “Consumers want access to higher quality products developed without using unhealthy chemicals that are currently used to avoid sprouting of potatoes stored at room temperature. The reduction in fried products of the potentially carcinogenic compound acrylamide will bring additional benefits to consumers.”
Plant Biotechnology Journal
Improving cold storage and processing traits in potato through targeted gene knockout
Benjamin M. Clasen, Thomas J. Stoddard, Song Luo, Zachary L. Demorest, Jin Li, Frederic Cedrone, Redeat Tibebu, Shawn Davison, Erin E. Ray, Aurelie Daulhac, Andrew Coffman, Ann Yabandith, Adam Retterath, William Haun, Nicholas J. Baltes, Luc Mathis, Daniel F. Voytas and Feng Zhang
Article first published online: April 7, 2015
DOI: 10.1111/pbi.12370
For further information, please contact:
Media contacts
Jennifer Moore, Director of Communications
Phone: 917-580-1088
email: contact@cellectis-plantsciences.com
BMC Communications - New York City
Brad Miles
Phone: 646-513-3125
email: bmiles@bmccommunications.com
IR contacts
Simon Harnest, VP Finance and Investor Relations
Phone: 646-385-9008
email: simon.harnest@cellectis.com
About Cellectis Plant Sciences
Founded in 2010, Cellectis Plant Sciences is based in New Brighton, Minnesota (United States). The company has developed a platform to improve the quality of crops for the food and agriculture industries. Cellectis Plant Sciences is involved in a network of collaborations that include global companies (Bayer, Limagrain, Monsanto, and SESVanderhave, among others), as well as leading healthcare (Mitsubishi Tanabe Pharma) and food companies. Cellectis Plant Sciences is developing innovative products with prominent partners in order to secure accessibility of its products to consumers.
For further information please visit our website: www.cellectis-plantsciences.com
Disclaimer
This press release contains forward-looking statements. You should not place undue reliance on such statements because they are subject to numerous risks and uncertainties relating to the company’s operations and business environment, all of which are difficult to predict and many are beyond the company’s control. Forward-looking statements include information concerning the company’s possible or assumed future results of operations, including descriptions of its business strategy. These statements often include words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or similar expressions. These factors are more fully discussed in the “Risk Factors” section and elsewhere in the company’s Registration Statement on Form F-1, as amended (File No. 333-202205). You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although the company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual financial results or results of operations and could cause actual results to differ materially from those in these forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.